For your patients with HIV‑associated wasting, recognize the symptoms and take action



Serostim® is indicated for the treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary.

The patients depicted on this website are not actual Serostim® patients unless otherwise stated.

Serostim® real patient Terry

Real Serostim®patient story

Learn about a real Serostim® patient with HIV-associated wasting

Statements in video are based on individual experience. Results may vary.

Serostim® provides statistically significant improvements in the 3 key symptoms of HIV‑associated wasting, as demonstrated in clinical trials1

HIV‑associated wasting is a serious condition that may be a concern for patients living with HIV, including those with undetectable viral loads and normal CD4 counts who are well controlled on antiretroviral therapy (ART).2,3

The 3 key symptoms of HIV‑associated wasting are loss of lean body mass (LBM) and body weight, and decreased physical endurance.

Serostim® is the only FDA approved treatment that is proven to increase LBM and body weight, and to improve physical endurance. For more than 25 years, Serostim® has been prescribed to treat patients with HIV‑associated wasting.


  1. Serostim® (somatropin) for injection [prescribing information]. Rockland, MA: EMD Serono, Inc.
  2. Wasserman P, Segal-Maurer S, Wehbeh W, Rubin DS. Wasting disease, chronic immune activation, and inflammation in the HIV‑infected patient. Top Clin Nutr. 2011;26(1):14-28.
  3. Erlandson KM, Li X, Abraham AG, et al. Long-term impact of HIV wasting on physical function. AIDS. 2016;30(3):445-454.